- Zacks Small Cap Research•10 days ago
CytoSorbents (CTSO) reported financial results for the second quarter ending June 30th. It was another very solid quarter with product revenue setting a new record, up 16% from its previous high, fueled by increasing reorders from existing accounts and, to a lesser degree, initial contribution from new customers. This marks the fifth consecutive period of sequential product sales growth which, coupled with the high quality of the growth drivers (i.e. Q2 total revenue, product sales and grant income were all just about dead-on with our estimates. Total revenue of $2.22M ($2.22M E) was also a new record and up 131% yoy and 23% sequentially. Product sales were $1.85M ($1.87M E), an increase of 140% from $773k in Q2 2015 (as a reminder 1H 2015 sales were negatively impacted by sales force restructuring) and up 16% from $1.60M in Q1 2016. Grant income was $370k ($350k E).
- PR Newswire•16 days ago
MONMOUTH JUNCTION, N.J., Aug. 9, 2016 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to prevent or treat ...
- PR Newswire•17 days agoCytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers
MONMOUTH JUNCTION, N.J., Aug. 8, 2016 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy company specializing in the purification of blood and bodily fluids, announced the award of $650,000 in funding through two separate Small Business Innovation Research (SBIR) grant contracts by the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue development of novel hemocompatible potassium binding polymers and substrates that can rapidly treat life-threatening hyperkalemia in critically-injured warfighters, civilian patients, and patients with impaired kidney function, such as dialysis patients. Hyperkalemia is defined as the excessive concentration of potassium in the blood. Potassium is an important electrolyte in the body that is present inside cells at high concentrations, with the amount in blood tightly regulated. Following injury to cells by, for example, trauma, burn injury, ischemia, or cytotoxic drugs, such cells will continuously leak high levels of potassium into the blood, resulting in hyperkalemia. The kidneys normally excrete excess potassium from the blood, but when compromised, as in critically-ill patients suffering from kidney failure or in chronic dialysis patients with end-stage kidney disease, the levels of blood potassium can rapidly rise unabated. When the potassium level in the blood exceeds a concentration of 6.0 mmol/L (normal 3.6 - 5.2 mmol/L), the risk of heart arrhythmias and sudden cardiac death increases significantly. Orally administered potassium sorbents such as Kayexalate® (Sanofi-Aventis) and Veltassa® (Relypsa) are only recommended for the non-emergent lowering of mild to moderate hyperkalemia, while the use of insulin and glucose to drive potassium into cells in severe hyperkalemia is only a temporary strategy. Dialysis has been the definitive treatment of severe hyperkalemia, but requires a large dialysis machine, an electrical wall socket, bags of dialysate, a skilled technician, and prolonged treatment times that are not practical in certain situations such as far-forward or remote areas. CytoSorbents is collaborating with leading military researchers to optimize prototype polymers capable of rapidly reducing serum potassium in large animal models, using simple "blood in, blood out" hemoperfusion systems and other strategies.
Cytosorbents Corporation (CTSO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Ask||10.50 x 200|
|Day's Range||4.82 - 5.02|
|52wk Range||3.11 - 8.10|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-12.54|
|Avg Vol (3m)||63,796|
|Dividend & Yield||N/A (N/A)|